Evofem Biosciences Inc. announced the launch of “Get Phexxi”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of the company’s non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi (lactic acid, citric acid and potassium bitartrate).
The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
The U.S. Supreme Court considered a bid by Donald Trump’s administration to implement rules allowing employers to obtain religious exemptions from an Obamacare requirement that health insurance that they provide to employees covers women’s birth control.
Amphora has the opportunity to completely disrupt the birth control market with a new viscous and bioadhesive contraceptive.
The Bill & Melinda Gates Foundation granted Watertown, Massachusetts-based Lyndra Therapeutics a $13 million grant to develop a once-a-month oral contraceptive.
For the eighth year, Med Ad News has chosen three Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Builds on Current Momentum Towards Broadening Access to This Contraceptive Option for Women Across the Globe September 24, 2015 12:01 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Pfizer Inc. […]